Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.

Autor:	Bateni SB; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Division of General Surgery, University of Toronto, Toronto, Ontario, Canada.; Division of Surgical Oncology, Department of Surgery, University of Alabama at Birmingham., Nguyen P; ICES at Queen's University, Kingston, Ontario, Canada., Eskander A; Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada.; Department of Otolaryngology-Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada., Seung SJ; Health Outcomes and PharmacoEconomics (HOPE) Research Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada., Mittmann N; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Jalink M; Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Ontario, Canada.; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada., Gupta A; Division of Hematology, Oncology, & Transplantation, University of Minnesota, Minneapolis., Chan KKW; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Look Hong NJ; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Hanna TP; ICES at Queen's University, Kingston, Ontario, Canada.; Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Ontario, Canada.; Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada.; Department of Oncology, Queen's University, Kingston, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	JAMA dermatology [JAMA Dermatol] 2023 Nov 01; Vol. 159 (11), pp. 1195-1204.
DOI:	10.1001/jamadermatol.2023.3179
Abstrakt:	Importance: Melanoma treatment has evolved during the past decade with the adoption of adjuvant and palliative immunotherapy and targeted therapies, with an unclear impact on health care costs and outcomes in routine practice. Objective: To examine changes in health care costs, overall survival (OS), and time toxicity associated with primary treatment of melanoma. Design, Setting, and Participants: This cohort study assessed a longitudinal, propensity score (PS)-matched, retrospective cohort of residents of Ontario, Canada, aged 20 years or older with stages II to IV cutaneous melanoma identified from the Ontario Cancer Registry from January 1, 2018, to March 31, 2019. A historical comparison cohort was identified from a population-based sample of invasive melanoma cases diagnosed from the Ontario Cancer Registry from January 1, 2007, to December 31, 2012. Data analysis was performed from October 17, 2022, to March 13, 2023. Exposures: Era of melanoma diagnosis (2007-2012 vs 2018-2019). Main Outcomes and Measures: The primary outcomes were mean per-capita health care and systemic therapy costs (Canadian dollars) during the first year after melanoma diagnosis, time toxicity (days with physical health care contact) within 1 year of initial treatment, and OS. Standardized differences were used to compare costs and time toxicity. Kaplan-Meier methods and Cox proportional hazards regression were used to compare OS among PS-matched cohorts. Results: A PS-matched cohort of 731 patients (mean [SD] age, 67.9 [14.8] years; 437 [59.8%] male) with melanoma from 2018 to 2019 and 731 patients (mean [SD] age, 67.9 [14.4] years; 440 [60.2%] male) from 2007 to 2012 were evaluated. The 2018 to 2019 patients had greater mean (SD) health care (including systemic therapy) costs compared with the 2007 to 2012 patients ($47 886 [$55 176] vs $33 347 [$31 576]), specifically for stage III ($67 108 [$57 226] vs $46 511 [$30 622]) and stage IV disease ($117 450 [$79 272] vs $47 739 [$37 652]). Mean (SD) systemic therapy costs were greater among 2018 to 2019 patients: stage II ($40 823 [$40 621] vs $10 309 [$12 176]), III ($55 699 [$41 181] vs $9764 [$12 771]), and IV disease ($79 358 [$50 442] vs $9318 [$14 986]). Overall survival was greater for the 2018 to 2019 cohort compared with the 2007 to 2012 cohort (3-year OS: 74.2% [95% CI, 70.8%-77.2%] vs 65.8% [95% CI, 62.2%-69.1%], hazard ratio, 0.72 [95% CI, 0.61-0.85]; P < .001). Time toxicity was similar between eras. Patients with stage IV disease spent more than 1 day per week (>52 days) with physical contact with the health care system by 2018 to 2019 (mean [SD], 58.7 [43.8] vs 44.2 [26.5] days; standardized difference, 0.40; P = .20). Conclusions and Relevance: This cohort study found greater health care costs in the treatment of stages II to IV melanoma and substantial time toxicity for patients with stage IV disease, with improvements in OS associated with the adoption of immunotherapy and targeted therapies. These health system-wide data highlight the trade-off with adoption of new therapies, for which there is a greater economic burden to the health care system and time burden to patients but an associated improvement in survival.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu